Schertz Bergmann Rechtsanwälte: Alexander Zverev

7.6.2024 14:12:44 CEST | news aktuell GmbH | Press release

Share

As lawyers for Alexander Zverev, we declare on behalf of our client that the criminal proceedings under file number 250 Cs 184/23 have been dropped.

The criminal proceedings against Alexander Zverev were dropped and the case was terminated today by the court with the consent of the public prosecutor's office, Ms. Brenda Patea as joint plaintiff and Alexander Zverev's defence lawyer.  The penalty order is now groundless.

Alexander Zverev has agreed to this discontinuation via his defense lawyer, solely in order to shorten the proceedings - above all in the interests of their child. Alexander Zverev is considered innocent. The dismissal does not constitute a finding of guilt or an admission of guilt. The legal presumption of innocence remains unaffected.

Dr. Anna Sophie Heuchemer (Schertz Bergmann Attorneys at law)     

Katharina Dierlamm (Dierlamm Attorneys at law)                 

 

Pressekontakt

Schertz Bergmann Rechtsanwälte PartG mbB

Kurfürstendamm 53

10707 Berlin

Tel.: 030 88 00 150

E-Mail:cs@schertz-bergmann.de

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Democracy News Alliance: Fiscal strength doesn't guarantee public goods delivery, US study finds21.10.2026 09:55:20 CEST | Press release

New York/DNA - A newly released study of US state government performance found strong partisan and regional patterns within three pillars of governance: democratic accountability, state capacity and public goods provision. Yet, the US states’ outcomes differ in important ways from international comparisons, as the three governance dimensions show limited correlation, the researchers found.

Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain20.10.2026 10:17:49 CEST | Press release

Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy surgery. Grünenthal anticipates reporting results in early 2028.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye